Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 221 entries
Sorted by: Best Match Show Resources per page
Pathogenic Effector Th2 Cells in Allergic Eosinophilic Inflammatory Disease.

Frontiers in medicine

Mitson-Salazar A, Prussin C.
PMID: 29057225
Front Med (Lausanne). 2017 Oct 06;4:165. doi: 10.3389/fmed.2017.00165. eCollection 2017.

There is an absolute requirement for Th2 cells in the pathogenesis of allergen-driven eosinophil-rich type 2 inflammation. Although Th2 cells are generally regarded as a homogeneous population, in the past decade there has been increasing evidence for a minority...

Cite
Mitson-Salazar A, Prussin C. Pathogenic Effector Th2 Cells in Allergic Eosinophilic Inflammatory Disease. Front Med (Lausanne). 2017;4:165doi: 10.3389/fmed.2017.00165.
Mitson-Salazar, A., & Prussin, C. (2017). Pathogenic Effector Th2 Cells in Allergic Eosinophilic Inflammatory Disease. Frontiers in medicine, 4165. https://doi.org/10.3389/fmed.2017.00165
Mitson-Salazar, Alyssa, and Prussin, Calman. "Pathogenic Effector Th2 Cells in Allergic Eosinophilic Inflammatory Disease." Frontiers in medicine vol. 4 (2017): 165. doi: https://doi.org/10.3389/fmed.2017.00165
Mitson-Salazar A, Prussin C. Pathogenic Effector Th2 Cells in Allergic Eosinophilic Inflammatory Disease. Front Med (Lausanne). 2017 Oct 06;4:165. doi: 10.3389/fmed.2017.00165. eCollection 2017. PMID: 29057225; PMCID: PMC5635264.
Copy Download .nbib Format: NLM
Revisiting the identification and cDNA cloning of T cell-replacing factor/interleukin-5.

Frontiers in immunology

Takatsu K.
PMID: 25566252
Front Immunol. 2014 Dec 23;5:639. doi: 10.3389/fimmu.2014.00639. eCollection 2014.

This is a perspective based on the paper "Cloning of complementary DNA encoding T cell-replacing factor and identity with B cell growth factor II," by Kinashi et al. (1). We have been interested in understanding the molecular basis of...

Cite
Takatsu K. Revisiting the identification and cDNA cloning of T cell-replacing factor/interleukin-5. Front Immunol. 2014;5:639doi: 10.3389/fimmu.2014.00639.
Takatsu, K. (2014). Revisiting the identification and cDNA cloning of T cell-replacing factor/interleukin-5. Frontiers in immunology, 5639. https://doi.org/10.3389/fimmu.2014.00639
Takatsu, Kiyoshi. "Revisiting the identification and cDNA cloning of T cell-replacing factor/interleukin-5." Frontiers in immunology vol. 5 (2014): 639. doi: https://doi.org/10.3389/fimmu.2014.00639
Takatsu K. Revisiting the identification and cDNA cloning of T cell-replacing factor/interleukin-5. Front Immunol. 2014 Dec 23;5:639. doi: 10.3389/fimmu.2014.00639. eCollection 2014. PMID: 25566252; PMCID: PMC4274987.
Copy Download .nbib Format: NLM
The Relevance of Circulating Interleukin-5 (IL-5) in Lymphoproliferative Disorders.

Hematology (Amsterdam, Netherlands)

Aladle DA, Salem MA, Mahmoud LA.
PMID: 27419603
Hematology. 2001;6(1):47-51. doi: 10.1080/10245332.2001.11746552.

It is well substantiated that several cytokines have a regulatory action on the neoplastic process of different lymphoproliferative disorders (LPDs). The objective of this study was to clarify the role of interleukin-5 (IL-5) as a factor in disease phenotype...

Cite
Aladle DA, Salem MA, Mahmoud LA. The Relevance of Circulating Interleukin-5 (IL-5) in Lymphoproliferative Disorders. Hematology. 2001;6(1):47-51doi: 10.1080/10245332.2001.11746552.
Aladle, D. A., Salem, M. A., & Mahmoud, L. A. (2001). The Relevance of Circulating Interleukin-5 (IL-5) in Lymphoproliferative Disorders. Hematology (Amsterdam, Netherlands), 6(1), 47-51. https://doi.org/10.1080/10245332.2001.11746552
Aladle, D A, et al. "The Relevance of Circulating Interleukin-5 (IL-5) in Lymphoproliferative Disorders." Hematology (Amsterdam, Netherlands) vol. 6,1 (2001): 47-51. doi: https://doi.org/10.1080/10245332.2001.11746552
Aladle DA, Salem MA, Mahmoud LA. The Relevance of Circulating Interleukin-5 (IL-5) in Lymphoproliferative Disorders. Hematology. 2001;6(1):47-51. doi: 10.1080/10245332.2001.11746552. PMID: 27419603.
Copy Download .nbib Format: NLM
Exposure to hypergravity increases serum interleukin-5 and pulmonary infiltration in mice with allergic asthma.

Central-European journal of immunology

Jang TY, Kim KS, Park CS, Lim J, Huh KC, Heo MJ, Jung AY, Kim YH.
PMID: 26155159
Cent Eur J Immunol. 2014;39(4):434-40. doi: 10.5114/ceji.2014.47725. Epub 2014 Dec 15.

OBJECTIVE: We evaluated the effect of acute hypergravity (HG) on the immune response in a murine model of allergic asthma.MATERIAL AND METHODS: Twenty-eight BALB/c mice were used. Group A (control group, n = 7) mice were sensitized and challenged...

Cite
Jang TY, Kim KS, Park CS, et al. Exposure to hypergravity increases serum interleukin-5 and pulmonary infiltration in mice with allergic asthma. Cent Eur J Immunol. 2014;39(4):434-40doi: 10.5114/ceji.2014.47725.
Jang, T. Y., Kim, K. S., Park, C. S., Lim, J., Huh, K. C., Heo, M. J., Jung, A. Y., & Kim, Y. H. (2014). Exposure to hypergravity increases serum interleukin-5 and pulmonary infiltration in mice with allergic asthma. Central-European journal of immunology, 39(4), 434-40. https://doi.org/10.5114/ceji.2014.47725
Jang, Tae Young, et al. "Exposure to hypergravity increases serum interleukin-5 and pulmonary infiltration in mice with allergic asthma." Central-European journal of immunology vol. 39,4 (2014): 434-40. doi: https://doi.org/10.5114/ceji.2014.47725
Jang TY, Kim KS, Park CS, Lim J, Huh KC, Heo MJ, Jung AY, Kim YH. Exposure to hypergravity increases serum interleukin-5 and pulmonary infiltration in mice with allergic asthma. Cent Eur J Immunol. 2014;39(4):434-40. doi: 10.5114/ceji.2014.47725. Epub 2014 Dec 15. PMID: 26155159; PMCID: PMC4439952.
Copy Download .nbib Format: NLM
Asthma: eosinophil disease, mast cell disease, or both?.

Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology

Bradding P.
PMID: 20525129
Allergy Asthma Clin Immunol. 2008 Jun 15;4(2):84-90. doi: 10.1186/1710-1492-4-2-84. Epub 2008 Jun 15.

: Although there is much circumstantial evidence implicating eosinophils as major orchestrators in the pathophysiology of asthma, recent studies have cast doubt on their importance. Not only does anti-interleukin-5 treatment not alter the course of the disease, but some...

Cite
Bradding P. Asthma: eosinophil disease, mast cell disease, or both?. Allergy Asthma Clin Immunol. 2008;4(2):84-90doi: 10.1186/1710-1492-4-2-84.
Bradding, P. (2008). Asthma: eosinophil disease, mast cell disease, or both?. Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology, 4(2), 84-90. https://doi.org/10.1186/1710-1492-4-2-84
Bradding, Peter. "Asthma: eosinophil disease, mast cell disease, or both?." Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology vol. 4,2 (2008): 84-90. doi: https://doi.org/10.1186/1710-1492-4-2-84
Bradding P. Asthma: eosinophil disease, mast cell disease, or both?. Allergy Asthma Clin Immunol. 2008 Jun 15;4(2):84-90. doi: 10.1186/1710-1492-4-2-84. Epub 2008 Jun 15. PMID: 20525129; PMCID: PMC2868886.
Copy Download .nbib Format: NLM
Update on the management of chronic eczema: new approaches and emerging treatment options.

Clinical, cosmetic and investigational dermatology

Walling HW, Swick BL.
PMID: 21437065
Clin Cosmet Investig Dermatol. 2010 Jul 28;3:99-117. doi: 10.2147/ccid.s6496.

Atopic dermatitis (AD) is a common disease with worldwide prevalence, affecting up to 20% of children and 3% of adults. Recent evidence regarding pathogenesis has implicated epidermal barrier defects deriving from filagrin mutations with resulting secondary inflammation. In this...

Cite
Walling HW, Swick BL. Update on the management of chronic eczema: new approaches and emerging treatment options. Clin Cosmet Investig Dermatol. 2010;3:99-117doi: 10.2147/ccid.s6496.
Walling, H. W., & Swick, B. L. (2010). Update on the management of chronic eczema: new approaches and emerging treatment options. Clinical, cosmetic and investigational dermatology, 399-117. https://doi.org/10.2147/ccid.s6496
Walling, Hobart W, and Swick, Brian L. "Update on the management of chronic eczema: new approaches and emerging treatment options." Clinical, cosmetic and investigational dermatology vol. 3 (2010): 99-117. doi: https://doi.org/10.2147/ccid.s6496
Walling HW, Swick BL. Update on the management of chronic eczema: new approaches and emerging treatment options. Clin Cosmet Investig Dermatol. 2010 Jul 28;3:99-117. doi: 10.2147/ccid.s6496. PMID: 21437065; PMCID: PMC3047944.
Copy Download .nbib Format: NLM
Eosinophilic panniculitis presenting with Kaposi's sarcoma-like plaques in a patient who is human immunodeficiency virus positive: a case report.

Journal of medical case reports

Ustuner P, Dilek N, Saral Y, Dilek AR, Bedir R.
PMID: 23148793
J Med Case Rep. 2012 Nov 13;6:387. doi: 10.1186/1752-1947-6-387.

INTRODUCTION: Eosinophilic panniculitis is an unusual type of panniculitis characterized by a prominent infiltration of subcutaneous fat with eosinophils without an exact etiopathogenesis. To the best of our knowledge, up to now eosinophilic panniculitis has been described in only...

Cite
Ustuner P, Dilek N, Saral Y, et al. Eosinophilic panniculitis presenting with Kaposi's sarcoma-like plaques in a patient who is human immunodeficiency virus positive: a case report. J Med Case Rep. 2012;6:387doi: 10.1186/1752-1947-6-387.
Ustuner, P., Dilek, N., Saral, Y., Dilek, A. R., & Bedir, R. (2012). Eosinophilic panniculitis presenting with Kaposi's sarcoma-like plaques in a patient who is human immunodeficiency virus positive: a case report. Journal of medical case reports, 6387. https://doi.org/10.1186/1752-1947-6-387
Ustuner, Pelin, et al. "Eosinophilic panniculitis presenting with Kaposi's sarcoma-like plaques in a patient who is human immunodeficiency virus positive: a case report." Journal of medical case reports vol. 6 (2012): 387. doi: https://doi.org/10.1186/1752-1947-6-387
Ustuner P, Dilek N, Saral Y, Dilek AR, Bedir R. Eosinophilic panniculitis presenting with Kaposi's sarcoma-like plaques in a patient who is human immunodeficiency virus positive: a case report. J Med Case Rep. 2012 Nov 13;6:387. doi: 10.1186/1752-1947-6-387. PMID: 23148793; PMCID: PMC3514367.
Copy Download .nbib Format: NLM
Influence of carbohydrate ingestion on salivary immunoglobulin A following resistance exercise.

Journal of the International Society of Sports Nutrition

Carlson LA, Kenefick RW, Koch AJ.
PMID: 23514330
J Int Soc Sports Nutr. 2013 Mar 20;10(1):14. doi: 10.1186/1550-2783-10-14.

BACKGROUND: Heavy exercise stresses immune function, however carbohydrate (CHO) supplementation has been shown to attenuate the decline in some measures of immune function after exercise. The purpose of the study was to investigate the impact of CHO supplementation on...

Cite
Carlson LA, Kenefick RW, Koch AJ. Influence of carbohydrate ingestion on salivary immunoglobulin A following resistance exercise. J Int Soc Sports Nutr. 2013;10(1):14doi: 10.1186/1550-2783-10-14.
Carlson, L. A., Kenefick, R. W., & Koch, A. J. (2013). Influence of carbohydrate ingestion on salivary immunoglobulin A following resistance exercise. Journal of the International Society of Sports Nutrition, 10(1), 14. https://doi.org/10.1186/1550-2783-10-14
Carlson, Lara A, et al. "Influence of carbohydrate ingestion on salivary immunoglobulin A following resistance exercise." Journal of the International Society of Sports Nutrition vol. 10,1 (2013): 14. doi: https://doi.org/10.1186/1550-2783-10-14
Carlson LA, Kenefick RW, Koch AJ. Influence of carbohydrate ingestion on salivary immunoglobulin A following resistance exercise. J Int Soc Sports Nutr. 2013 Mar 20;10(1):14. doi: 10.1186/1550-2783-10-14. PMID: 23514330; PMCID: PMC3726298.
Copy Download .nbib Format: NLM
Severe, eosinophilic asthma in primary care in Canada: a longitudinal study of the clinical burden and economic impact based on linked electronic medical record data.

Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology

Husereau D, Goodfield J, Leigh R, Borrelli R, Cloutier M, Gendron A.
PMID: 29713354
Allergy Asthma Clin Immunol. 2018 Apr 24;14:15. doi: 10.1186/s13223-018-0241-1. eCollection 2018.

BACKGROUND: Stratification of patients with severe asthma by blood eosinophil counts predicts responders to anti-interleukin (IL)-5 (mepolizumab and reslizumab) and anti-IL-5 receptor α (benralizumab) therapies. This study characterized patients with severe asthma who could qualify for these biologics in...

Cite
Husereau D, Goodfield J, Leigh R, et al. Severe, eosinophilic asthma in primary care in Canada: a longitudinal study of the clinical burden and economic impact based on linked electronic medical record data. Allergy Asthma Clin Immunol. 2018;14:15doi: 10.1186/s13223-018-0241-1.
Husereau, D., Goodfield, J., Leigh, R., Borrelli, R., Cloutier, M., & Gendron, A. (2018). Severe, eosinophilic asthma in primary care in Canada: a longitudinal study of the clinical burden and economic impact based on linked electronic medical record data. Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology, 1415. https://doi.org/10.1186/s13223-018-0241-1
Husereau, Don, et al. "Severe, eosinophilic asthma in primary care in Canada: a longitudinal study of the clinical burden and economic impact based on linked electronic medical record data." Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology vol. 14 (2018): 15. doi: https://doi.org/10.1186/s13223-018-0241-1
Husereau D, Goodfield J, Leigh R, Borrelli R, Cloutier M, Gendron A. Severe, eosinophilic asthma in primary care in Canada: a longitudinal study of the clinical burden and economic impact based on linked electronic medical record data. Allergy Asthma Clin Immunol. 2018 Apr 24;14:15. doi: 10.1186/s13223-018-0241-1. eCollection 2018. PMID: 29713354; PMCID: PMC5913870.
Copy Download .nbib Format: NLM
[The inflammatory pattern and the characteristics of mucous remodeling in different immune type of nasal polyps].

Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology, head, and neck surgery

Ba L, Du JT, Cai SY, Li J, Zhou P, Liu YF.
PMID: 29797975
Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2016 Aug 20;30(16):1302-1307. doi: 10.13201/j.issn.1001-1781.2016.16.010.

No abstract available.

Cite
Ba L, Du JT, Cai SY, et al. [The inflammatory pattern and the characteristics of mucous remodeling in different immune type of nasal polyps]. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2016;30(16):1302-1307doi: 10.13201/j.issn.1001-1781.2016.16.010.
Ba, L., Du, J. T., Cai, S. Y., Li, J., Zhou, P., & Liu, Y. F. (2016). [The inflammatory pattern and the characteristics of mucous remodeling in different immune type of nasal polyps]. Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology, head, and neck surgery, 30(16), 1302-1307. https://doi.org/10.13201/j.issn.1001-1781.2016.16.010
Ba, L, et al. "[The inflammatory pattern and the characteristics of mucous remodeling in different immune type of nasal polyps]." Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology, head, and neck surgery vol. 30,16 (2016): 1302-1307. doi: https://doi.org/10.13201/j.issn.1001-1781.2016.16.010
Ba L, Du JT, Cai SY, Li J, Zhou P, Liu YF. [The inflammatory pattern and the characteristics of mucous remodeling in different immune type of nasal polyps]. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2016 Aug 20;30(16):1302-1307. doi: 10.13201/j.issn.1001-1781.2016.16.010. Chinese. PMID: 29797975.
Copy Download .nbib Format: NLM
Editorial: Pathogenic Advances and Therapeutic Perspectives for Eosinophilic Inflammation.

Frontiers in medicine

Roufosse FE, Johansson MW.
PMID: 30234117
Front Med (Lausanne). 2018 Aug 31;5:243. doi: 10.3389/fmed.2018.00243. eCollection 2018.

No abstract available.

Cite
Roufosse FE, Johansson MW. Editorial: Pathogenic Advances and Therapeutic Perspectives for Eosinophilic Inflammation. Front Med (Lausanne). 2018;5:243doi: 10.3389/fmed.2018.00243.
Roufosse, F. E., & Johansson, M. W. (2018). Editorial: Pathogenic Advances and Therapeutic Perspectives for Eosinophilic Inflammation. Frontiers in medicine, 5243. https://doi.org/10.3389/fmed.2018.00243
Roufosse, Florence E, and Johansson, Mats W. "Editorial: Pathogenic Advances and Therapeutic Perspectives for Eosinophilic Inflammation." Frontiers in medicine vol. 5 (2018): 243. doi: https://doi.org/10.3389/fmed.2018.00243
Roufosse FE, Johansson MW. Editorial: Pathogenic Advances and Therapeutic Perspectives for Eosinophilic Inflammation. Front Med (Lausanne). 2018 Aug 31;5:243. doi: 10.3389/fmed.2018.00243. eCollection 2018. PMID: 30234117; PMCID: PMC6127289.
Copy Download .nbib Format: NLM
Lung microbiome and host immune tone in subjects with idiopathic pulmonary fibrosis treated with inhaled interferon-γ.

ERJ open research

Wang J, Lesko M, Badri MH, Kapoor BC, Wu BG, Li Y, Smaldone GC, Bonneau R, Kurtz ZD, Condos R, Segal LN.
PMID: 28717640
ERJ Open Res. 2017 Jul 12;3(3). doi: 10.1183/23120541.00008-2017. eCollection 2017 Jul.

Therapies targeting inflammation reveal inconsistent results in idiopathic pulmonary fibrosis (IPF). Aerosolised interferon (IFN)-γ has been proposed as a novel therapy. Changes in the host airway microbiome are associated with the inflammatory milieu and may be associated with disease...

Cite
Wang J, Lesko M, Badri MH, et al. Lung microbiome and host immune tone in subjects with idiopathic pulmonary fibrosis treated with inhaled interferon-γ. ERJ Open Res. 2017;3(3)doi: 10.1183/23120541.00008-2017.
Wang, J., Lesko, M., Badri, M. H., Kapoor, B. C., Wu, B. G., Li, Y., Smaldone, G. C., Bonneau, R., Kurtz, Z. D., Condos, R., & Segal, L. N. (2017). Lung microbiome and host immune tone in subjects with idiopathic pulmonary fibrosis treated with inhaled interferon-γ. ERJ open research, 3(3), . https://doi.org/10.1183/23120541.00008-2017
Wang, Jing, et al. "Lung microbiome and host immune tone in subjects with idiopathic pulmonary fibrosis treated with inhaled interferon-γ." ERJ open research vol. 3,3 (2017). doi: https://doi.org/10.1183/23120541.00008-2017
Wang J, Lesko M, Badri MH, Kapoor BC, Wu BG, Li Y, Smaldone GC, Bonneau R, Kurtz ZD, Condos R, Segal LN. Lung microbiome and host immune tone in subjects with idiopathic pulmonary fibrosis treated with inhaled interferon-γ. ERJ Open Res. 2017 Jul 12;3(3). doi: 10.1183/23120541.00008-2017. eCollection 2017 Jul. PMID: 28717640; PMCID: PMC5507144.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 221 entries